Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06807281 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Name: A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — clinical trial record (NCT06807281)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorPfizer

Started2025-12-02

View on ClinicalTrials.gov ↗

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

Amendment history 3 changes detected by DataLookout

2026-09-05

Trial sites expanded: 38 → 41 locations

2026-07-23

Trial sites expanded: 31 → 37 locations

2026-04-08

Trial sites expanded: 26 → 31 locations

Trial Details

NCT Number	NCT06807281
Lead Sponsor	Pfizer
Conditions	Atopic Dermatitis
Enrollment	500 participants
Start Date	2025-12-02
Primary Completion	2032-02-22 (estimated)
Study Completion	2032-02-22 (estimated)
Updated on ClinicalTrials.gov	2026-09-04